key: cord-0908951-rjnukoq2
authors: Shane, Andi L; Sato, Alice I; Kao, Carol; Adler-Shohet, Felice C; Vora, Surabhi B; Auletta, Jeffery J; Nachman, Sharon; Raabe, Vanessa N; Inagaki, Kengo; Akinboyo, Ibukunoluwa C; Woods, Charles; Alsulami, Abdulsalam O; Kainth, Mundeep K; Santos, Roberto Parulan; Espinosa, Claudia M; Burns, Julianne E; Cunningham, Coleen K; Dominguez, Samuel R; Larru Martinez, Beatriz; Zhu, Frank; Crews, Jonathan; Kitano, Taito; Saiman, Lisa; Kotloff, Karen
title: A Pediatric Infectious Disease Perspective of SARS-CoV-2 and COVID-19 in Children
date: 2020-08-25
journal: J Pediatric Infect Dis Soc
DOI: 10.1093/jpids/piaa099
sha: dabcf3225bfebe1c355dac2c3b59658da871be70
doc_id: 908951
cord_uid: rjnukoq2

Understanding the role that children play in the clinical burden and propagation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for novel coronavirus (COVID-19) infections is emerging. While the severe manifestations and acute clinical burden of COVID-19 has largely spared children compared to adults, understanding the epidemiology, clinical presentation, diagnostics, management, and prevention opportunities as well as the social and behavioral impacts on child health is vital. Foremost is clarifying the contribution of asymptomatic and mild infections to transmission within the household and community and the clinical and epidemiologic significance of uncommon severe post-infectious complications. Herein we summarize the current knowledge, identify useful resources, and outline research opportunities. Pediatric infectious disease clinicians have a unique opportunity to advocate for the inclusion of children in epidemiological, clinical, treatment and prevention studies to optimize their care, as well as to represent children in the development of guidance and policy during pandemic response.

A c c e p t e d M a n u s c r i p t 6 

In December 2019, Coronavirus Disease 2019 (COVID-19) emerged in Wuhan, China, and the etiology was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the end of January 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern, and by mid-March 2020, the outbreak was declared a pandemic. Initially, children comprised between 1 to 2% of the laboratory confirmed SARS-CoV-2 detections among people in China [1] , Italy [2] , and the United States [3] . Initial reports from the Centers for Disease Control and Prevention (CDC) noted that the following age distributions: 15-17 years (32%), 10-14 years (27%), 5-9 years (15%), 1-4 years (11%), and <1 year (15%), with a median age of 11 years [3] . Subsequent assessments, as access to diagnostic testing increased, demonstrated that children, defined in this cohort as birth to 19 years of age, comprised 5.2% of the laboratory confirmed test results submitted to the from 22 January -30 May 2020 [4] . Among this subsequent surveillance effort, specimens from children from birth through 9 years of age comprised 1.5% of the total positive results while those from 10 through 19 years of age comprised 3.7% of the total 5.2%. Internationally, most children who met either a laboratory or clinical definition for detecting SARS-CoV-2 or having a COVID-19 have been school-aged and adolescents. The low proportion of confirmed infections in infants and younger children probably results from the propensity of infants and young children to have mild symptoms and thus remain undetected [5] . A retrospective cohort study of contacts of patients with COVID-19 in Shenzhen, China found similar infection attack rates across pediatric age groups. Among children 0-9 years, the secondary attack rate was 7.4% (95% confidence interval (CI) 4. 2-12.8 ) and among those 10-17 years of age, the secondary attack rate was 7.1% (95% CI 3.3-14.6) [6] . In a household transmission study in Guangzhou, China, researchers reported that the risk of household infection was lower in the youngest age group (<20 years; odds ratio [OR] 0.23 [95% CI 0.11-0.46]) compared with household contacts over 60 years of age [7] . Challenges with interpretation of epidemiological studies in A c c e p t e d M a n u s c r i p t 7 children include the variation among upper limit age parameters for classification as a child, varying clinical and laboratory parameters for classifying as a related infection, and a lack of representative samples from both symptomatic and asymptomatic children. These factors likely impact differences in the descriptive epidemiology of children with COVID-19.

Estimates of R 0 have varied across studies. Like factors impacting epidemiological classification, the setting, degree of crowding, adherence to controls measures, and extent of diagnostic testing affect R 0 estimates. Data from China early in the epidemic suggesting a median R 0 of 2-3 are widely accepted [8] ; however, recent modeling suggests that the R 0 value may be much higher at 5.7 (95% CI 3.8-8.9) [9] .

The incubation period of SARS-CoV-2 is estimated to be 5.2 days (95% CI 4.1 to 7.0 days), with a range of 2-14 days [10] [11] . Failure to account for transmission from mildly symptomatic individuals makes defining the incubation period in children more challenging.

Transmission is primarily through respiratory droplets or close contact [12] . The contribution of transmission via aerosolized particles remains controversial. Transmission from presymptomatic (within 48-72 hours before signs and symptoms appear) [13, 14] and asymptomatically [15] infected children have been suggested [16] . This has also been observed with influenza [17] , and other respiratory viral infections, when asymptomatic or sub-clinically infected children elude case detection. Case series suggest that the majority (80-84%) of infected children have a symptomatic adult household or other direct epidemiologic close contact [18] .

There are reasons to suspect that children may represent an important reservoir of infection within the community, especially those with higher viral loads who escape recognition because they manifest less severe disease [19] [20] . Although symptomatic children have demonstrated higher viral loads from nasopharyngeal specimens than asymptomatic children [21] an understanding of how viral load corresponds with transmission is evolving.

Detectable SARS-CoV-2 from the nasopharynx for up to 22 days following symptom onset M a n u s c r i p t 8 and for up to 30 days following symptom onset from pediatric fecal samples demonstrates the challenge of interpreting the significance of prolonged and variable shedding from different anatomical sites [18, 22] [23]. The association seen in adults of a greater severity of disease with higher viral loads and longer shedding of SARS-CoV-2 may not hold in children [24] . Moreover, polymerase chain reaction (PCR) detection of viral RNA may not represent infectious virus particles. The ongoing accumulation of information related to serological correlates of protection following both symptomatic and asymptomatic infections will add to our understanding of transmissibility in recovered children [25] .

Underlying health conditions are common in hospitalized children with acute COVID-19, including chronic respiratory insufficiency, obesity, and neurodevelopmental conditions [4] [26] [27] [28] . It is unclear whether the increased hospitalization rate among children with underlying medical conditions is due to a lower threshold for hospitalization, concern for complications, or more severe manifestations of a SARS CoV-2 infection. Several case series have described the clinical features of SARS-CoV-2 infection in children from the perspective of disease severity, presenting symptoms, and in comparison to those described in adults. A consistent picture of a generally mild disease in children has emerged from settings in Asia, North America, and Europe. More than 96% of children reported to the equivalent of the Chinese CDC with laboratory confirmed SARS-CoV-2 infections had mild or moderate illness (fever, respiratory symptoms, or radiographic pneumonia without hypoxemia). Less than 3% had severe disease requiring oxygen supplementation and < 1% (3 children) were considered to be critically ill [29] . In several case series, most children were identified based on symptoms, making rates of infection in asymptomatic children unknown.

Among 17,877 children who had symptoms reported to the U.S. CDC, the most common symptoms were fever (46%), cough (37%), headache (15%), diarrhea (14%), and sore throat (13%) in children < 9 years and headache (42%), cough (41%), fever (35%), myalgia (30%), sore throat (29%), shortness of breath (16%), and diarrhea (14%) in children 10 -19 years M a n u s c r i p t 9 of age. Other less commonly reported symptoms included rhinorrhea, nausea/vomiting, abdominal pain, and anosmia and dysgeusia [4] . Among a cohort of 50 hospitalized children (< 21 years of age) in New York City, the median time from symptom onset to hospitalization was 2 days with a median length of hospitalization of 3 days. Forty (80%) had fever and 32 (64%) respiratory symptoms with infants less likely to have respiratory symptoms compared with older children. Sixteen (8%) had a viral co-detection and 20 (40%) had a presumptive or confirmed bacterial co-infection. Sixteen (32%) required respiratory support and 9 (16%) required assisted ventilation [30] . A cohort of 65 children receiving care in a New York City area health system demonstrated similar demographics with 35% of patients requiring intensive-care-unit care. Severity was lowest in infants < 60 days of age and highest in chronically ill children; 79% of immunocompromised children had mild disease. One death was reported [28] . In comparison, a multinational systematic review of clinical information from 1780 children noted fever (52%), cough (47%), sore throat (18%) and severe illness in 0.6% [26] . [28].

The most common imaging abnormalities noted among Chinese children with both symptomatic and asymptomatic COVID-19 were pulmonary ground glass opacities or consolidation [43] . In a case series of 171 children from whom SARS-CoV-2 was detected, 56 (33%) had ground-glass opacities, 32 (19%) had local patchy shadowing, 21 (12%) had bilateral patchy shadowing, and 2 (1%) had interstitial abnormalities [44] . Another series found that bilateral infiltrates were more common than unilateral infiltrates; 4 (20%) children A c c e p t e d M a n u s c r i p t 12 had normal initial chest computerized tomography (CT) imaging [45] . Although children with more severe manifestations of disease were more likely to have imaging abnormalities [41] , this association may be due to ascertainment bias, as children with severe manifestations may be more likely to undergo imaging. Additionally, imaging abnormalities have been described in children with minimal to no recognized symptoms.

Most children with severe manifestations of COVID-19 completely recover. Accounting for access to diagnostic testing, children with underlying conditions appear to be most at risk for adverse outcomes. The spectrum of outcomes is described among 48 children cared for in pediatric intensive care units (PICU) in North America, 40 (83%) had an underlying medical condition. Although 18 (38%) of these children required mechanical ventilation and one patient required extracorporeal membrane oxygenation, the overall mortality was 4% among this North American PICU cohort [27] . In a case series from New York City, obesity and asthma were prevalent in the cohort but not significantly associated with PICU admission [46] . Prolonged courses of critical care have been reported in China for children with acute lymphocytic leukemia, hydronephrosis, and intussusception [42, 44, 47, 48] .

These generally favorable outcomes among children who experience clinically significant COVID-19 is an area of active exploration. Hypotheses that may explain the decreased severity of disease in children compared with adults include the lower expression of the angiotensin converting enzyme 2 (ACE 2) viral entry receptor in the lungs and nasal epithelia of children compared to adults [49] [50] , differences in innate immune responses that control viral killing and expression of inflammatory regulators involved in the ARDS pathway [51, 52] , cross protection from non-novel coronaviruses, exposure to vaccines with immunomodulating properties [53] , and the lower prevalence of underlying chronic medical conditions compared to adults and the elderly with COVID- 19 [54] . Routine testing for SARS-CoV-2 in women in a high prevalence city in the U.S., at the time of delivery of their infants, showed that one in eight women from whom SARS-CoV-2 was detected at the time of delivery, were asymptomatic [57]. Initial reports did not suggest a higher mortality or increased rates of complications among pregnant women from whom SARS-CoV-2 was detected [58] [59, 60]. Subsequently, ongoing CDC surveillance has noted that pregnant women in the U.S. with SARS-CoV-2 infections were more likely to be hospitalized than non-pregnant women for non-obstetric indications. Adjusting for cofounders, pregnant women were more likely to be cared for in an intensive care unit and to receive mechanical ventilation than non-pregnant women of childbearing age. Among 81% of 11,312 pregnant women with SARS-CoV-2 detection for whom information was available, 50% were of Hispanic or Latino ethnicity, 23% were White race and non-Hispanic ethnicity, 20% were Black race and non-Hispanic [61]. A high rate of acute respiratory distress syndrome was observed among a cohort of 64 pregnant women with severe or critical COVID-19 in the U.S. Half of the women were delivered during their third trimester; most of the infants born to the critically and severely ill women were premature. However, there were no maternal nor perinatal deaths in this cohort [62] .

Evidence for vertical transmission of SARS-CoV-2 has been sought from maternal-neonatal pairs. A case series of 33 SARS-CoV-2 infected mothers identified 3 (9%) neonates in whom websites is provided as reference for the most updated information regarding management (Table 1) .

Diagnosis of acute SARS-CoV-2 infection is a rapidly evolving field. Most assays utilize specific real-time RT PCR techniques [77, 78] . Numerous PCR assays approved only under the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) have been A c c e p t e d M a n u s c r i p t 17 extensively used in children [18, 29, 63, 79] . Although the nucleocapsid gene has been the primary target, some assays have included other viral target sequences [73, 78] . Molecular testing is the optimal diagnostic test for detection of SARS-CoV-2 in a person suspected of having an acute COVID-19.

For diagnostic testing for SARS-CoV-2, CDC recommends collecting and testing an upper respiratory specimen, preferably a nasopharyngeal specimen [80] . The diagnostic utility of saliva specimens, antigen testing, and self-collected nasal specimens are being assessed in adults and will need to be validated in children. Non-respiratory sites, including stool, have been evaluated in infants and children using research-based assays to detect SARS-CoV-2 RNA, but FDA EUA approved commercially available assays are currently not available for stool specimens. To conform to EUA guidance, users should note the anatomical sites for which an approved SARS-CoV-2 assay is validated.

Antibody assays that detect IgM and IgG may be reactive as early as 4 days after symptom onset [54], until as late as 11-14 days from date of infection [81] , impacting the utility of serology as a diagnostic modality. Serological assays approved under the FDA EUA [82] have largely used adult specimens for validation and raise the question about applicability in children, especially with respect to cross-reactivity to the non-novel coronaviruses [83] .

Serologic assays may be helpful to describe the epidemiology of SARS-CoV-2 retrospectively, but population samples will be a key factor in interpreting the results.

Although detection of another respiratory virus does not eliminate the possibility of SARS-CoV-2 co-infection, at the beginning of the pandemic, many public health entities suggested that detection of a non-SARS-CoV-2 respiratory organism was enough evidence to exclude a COVID-19. In part, this triage system was based upon limited access to acute diagnostic capability at the time, which also coincided with an end to the respiratory viral season.

Among 161 hospitalized children (≤14 years of age) with positive respiratory virus PCR assays enrolled in a retrospective study, two (1%) were coinfected with human respiratory Table 2 . Additional investigational COVID-19 therapeutics with ongoing or upcoming planned human trials can be found on ClinicalTrials.gov (https://clinicaltrials.gov/ct2/results?cond=COVID-19).

Following the finding that the antiviral remdesivir was superior to placebo in shortening the time to recovery and reducing mortality in adults hospitalized with lower respiratory tract 

SARS-CoV-2 is spread by respiratory droplets or close contact [94] facilitating transmission in grouped care arrangements. Person-to-person transmission as well as healthcareassociated transmissions have been described [95] . The extent of transmission by aerosols remains controversial. The virus is not believed to be spread by food. Emerging data A c c e p t e d M a n u s c r i p t 20 supporting lack of infectivity with prolonged shedding after 9 to 10 days has helped to guide isolation and quarantine guidance within healthcare settings and in the community [96] [97] .

As with all infectious diseases, the principles of Identify, Isolate and Inform may be applied to the management of children with known or suspected COVID-19. The unique aspects related to care of children with known or suspected COVID-19 center on maintaining a balance between family-centered care and healthcare worker safety ( Table 3) . Table 3 .

As part of the preparedness response, many pediatric healthcare entities have provided resources to adult healthcare systems, given the greater clinical impact of COVID-19 among adults. While the burden of clinical disease has been notably less in children, the psychosocial impact has been profound. Accustomed to socialization and interaction, children separated from their peer group have experienced the adverse effects of physical and social distancing manifest as depression, anxiety, and loss of developmental milestones. An estimated 188 countries imposed countrywide school closures affecting more than 1.5 billion children [99] . While a systematic review estimated that school closures may A c c e p t e d M a n u s c r i p t 21 contribute a 2 to 4% reduction in COVID-19 associated deaths [100] , emerging evidence supports the hypothesis that children are not the primary propagators of infection [101] [102] and that reopening schools provides an essential service to children and their communities [103] . The timing and extent of school reopening is a multidisciplinary decision that should consider local epidemiology and resources, while engaging Pediatric Infectious Disease clinicians. The CDC [104] and AAP [105] have developed guidance to assist policymakers with strategies to safely open schools by optimizing infection prevention, surveillance, and developing inclusion and exclusion approaches in collaboration with local public health authorities.

In addition to disruption of their peer groups, some children may have one, both, or all caregivers debilitated by illness, resulting in interruption of delivery of care. In many instances, preventive care, including immunization delivery, has been delayed [106] .

Non-hospital institutional systems that house or provide care to children and adolescents may be adversely impacted by ill residents or staff. Many ambulatory group and chronic care facilities for children have been unable to continue operations due to their inability to comply with requirements related to social distancing in the provision of care [107] , resulting in discontinuation of essential services. Transmission of SARS-CoV-2 in an overnight summer camp setting resulted in high attack rates among persons in all age groups. Asymptomatic infection potentially contributed to undetected transmission; assessment of clinical impact is ongoing. Use of face coverings and other preventive strategies were not universal [108] .

This report also questions the utility of pre-attendance, asymptomatic SARS-CoV-2 PCR testing, collected up to 12 days in advance of participation in a congregate activity.

As we learn more about the impact of SARS-CoV-2 on children, the adults who care for them, and the impact of management and containment strategies, questions related to the A c c e p t e d M a n u s c r i p t 22 management of children during a pandemic have emerged (Table 4 ). While we gain a greater understanding of the clinical impact and epidemiology of SARS-CoV-2, we must continue to advocate for the inclusion of children in clinical research, treatment, and prevention trials. Pediatric infectious disease clinicians and researchers are uniquely poised to partner with pediatricians, health departments, and policymakers to develop guidance that incorporates the unique needs of children and the communities in which they reside. M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

A c c e p t e d M a n u s c r i p t

Characteristics of and Important Lessons From the

COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Coronavirus Disease 2019 (COVID-19) in Italy

COVID-19 Clinical Response Team. Coronavirus Disease 2019 in Children -United States

Coronavirus Disease 2019 Case Surveillance -United States

Age-dependent effects in the transmission and control of COVID-19 epidemics

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study

Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

Characteristics of COVID-19 infection in Beijing

A comparative-descriptive analysis of clinical characteristics in 2019-coronavirus-infected children and adults

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

A COVID-19 Transmission within a family cluster by presymptomatic infectors in China

Presymptomatic Transmission of SARS-CoV-2 -Singapore

Asymptomatic cases in a family cluster with SARS-CoV-2 infection

Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic

Effectiveness of a School-Based Influenza Vaccination Intervention

A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19)

Symptomatic Infants have Higher Nasopharyngeal SARS-CoV-2 Viral Loads but Less Severe Disease than Older Children

Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19

Clinical and CT features in pediatric patients with COVID-19infection: Different points from adults

Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center

China's first child severe new coronavirus pneumonia

A 55-Day-Old Female Infant Infected With 2019 Novel Coronavirus Disease: Presenting With Pneumonia, Liver Injury, and Heart Damage

Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study

Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults

Mechanisms of acute respiratory distress syndrome in children and adults: a review and suggestions for future research

Lessons from COVID-19 in children: Key hypotheses to guide preventative and therapeutic strategies

National Immunization Campaigns with Oral Polio Vaccine Reduce All-Cause Mortality: A Natural Experiment within Seven Randomized Trials

Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study

Neonatal Early-Onset Infection With SARS-CoV-2 in 33

Neonates Born to Mothers With COVID-19 in Wuhan, China

Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection

Placental pathology in COVID-19

In-utero mother to child SARS−CoV−2 transmission: viral detection and fetal immune response

INITIAL GUIDANCE: Management of Infants Born to Mothers with COVID-19: Date of Document

Q&A on COVID-19 and breastfeeding

Challenges posed by COVID-19 to children with cancer

Managing Cancer Care During the COVID-19

Pandemic: Agility and Collaboration Toward a Common Goal

How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat?

The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage

COVID-19: A global transplant perspective on successfully navigating a pandemic

Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment

Clinical characteristics and outcome of SARS-CoV-2 infection in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the AIEOP

US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19). Available at

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease

United States Food and Drug Administration

What's New With the Old Coronaviruses?

Coinfection of SARS-CoV-2 and multiple respiratory pathogens in children

Co-infection and Other Clinical Characteristics of COVID-19 in Children

Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure

Centers for Disease Control and Prevention. Information for Clinicians on Therapeutic Options for COVID-19 Patients. Available at

Clinical management of severe acute respiratory infection when novel conornavirus (2019-nCoV) infection is supected

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Available at

Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2

Remdesivir for the Treatment of Covid-19 -Preliminary Report

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus

Characteristics of and Important Lessons From the

COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Centers for Disease Control Korea. Findings from investigation and analysis of repositive cases

Handbook of Pediatric Infection Prevention and Control: Pathogens Spread Via Respiratory Route First ed

The United Nations. Policy Brief: The Impact of COVID-19 on children

School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review

COVID-19 Transmission and Children: The Child Is Not to Blame

COVID-19 in Children and the Dynamics of Infection in Families

Reopening Primary Schools during the Pandemic

Considerations for Schools: Operating Schools During COVID-19

COVID-19 Planning Considerations: Guidance for School Re-entry

Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration -United States

The National Council on Behavioral Health. COVID-19 for Behavioral Health Residential Facilities

SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp -Georgia

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease

Controlled Trial of Ebola Virus Disease Therapeutics

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene

Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities

Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

A c c e p t e d M a n u s c r i p t